Anuncio • May 08
StageZero Life Sciences Ltd. announced that it expects to receive CAD 2 million in funding StageZero Life Sciences Ltd. announced a private placement transaction of of either, or a combination of: (i) up to CAD 2,000,000 of non-convertible notes bearing an interest rate of between 12 % to 14 per % per annum; or a convertible debt offering up to CAD 800,000 of units; each unit consisting of CAD 1,000 principal amount of unsecured convertible debentures bearing an interest rate of 8 % per annum, and 12,500 common share purchase warrants, provided that the aggregate gross proceeds from the debt offering and the convertible debt offering would not exceed CAD 2,000,000 on a combined basis on May 7, 2025. Each warrant is exercisable for one common share of the issuer. The principal amount of the convertible debentures may be converted by the holders into common shares at a floor conversion price to be determined based on the market price of the issuer's common shares on the Toronto Stock Exchange following recommencement of trading of the issuer's common shares on TSX (as required by applicable TSX policies). Each warrant shall be exercisable to purchase a common share at an exercise price that will be three cents higher than the market price for a period of 18 months. The proposed financing is subject to the approval of the TSX. Anuncio • Apr 03
StageZero Life Sciences Ltd. to Report Q4, 2023 Results on May 31, 2024 StageZero Life Sciences Ltd. announced that they will report Q4, 2023 results on May 31, 2024 Reported Earnings • Nov 16
Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0 in 3Q 2022) Third quarter 2023 results: US$0.01 loss per share (further deteriorated from US$0 in 3Q 2022). Revenue: US$745.5k (down 6.7% from 3Q 2022). Net loss: US$821.9k (loss widened US$776.8k from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. Anuncio • Nov 08
StageZero Life Sciences, Ltd. Clinical Business Introduces Fourth Pillar to Cancer Offerings StageZero Life Sciences Ltd. announced that its Clinical Business, Care Oncology, has added the fourth of a series of new program offerings. Pinky Jimenez-Agrawal, with WellnessScript, will provide mental health support specifically for cancer patients at twice-monthly clinics. The first clinic is Thursday November 9, 2023 and is open to patients globally. Screening to find cancer early is the first pillar (AristotleTM); adjunctive treatment with the Care Oncology Protocol is the second; nutritional guidance tailored to the type and stage of the cancer is the third pillar and mental health support is the fourth pillar. The Company believes that these additional offerings present an excellent entry point for cancer patients to be introduced to the full Care Oncology program. One in three patients with cancer have challenges with mental health: up to 25% of cancer survivors suffer from depression and up to 45% with anxiety. Supporting individuals on their journey towards recovery as well as offering help to terminally ill patients and their families as they prepare for death, is a key aspect of her work. She runs bimonthly drop-in sessions, and provides psychological support on a 1:1 basis, for the members of a leukaemia charity. As a volunteer therapist for Cruse Bereavement Care, she provides counselling to children and young adults. She's an ACT practitioner and a DBT informed therapist. She uses a combination of therapies and mindfulness-based interventions. Her work helps individuals build on their strengths by helping them learn new skills, expand from their own experience and teach strategies to enable them to cope with their issues and develop better well-being habits. The program will be offered virtually, twice a month. The program is open to anyone, not just Care Oncology patients and with times to allow global participation. Interested individuals can sign up at [1]. Participants will pay directly for each session. Care Oncology offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Care Oncology has been treating cancer patients since 2013 using patented COC Protocol™?. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use. In addition to the COC Protocol, Care Oncology offers the AVRT preventative program. All of the Care Oncology programs are managed by a multi-disciplinary team that is overseen by Oncologists and includes Nurse practitioners and Metabolic Specialists. Anuncio • Oct 21
Stagezero Life Sciences, Ltd. Clinical Business Introduces Third Pillar to Cancer Offerings StageZero Life Sciences Ltd. announced that its Clinical Business Care Oncology, has added the first of a series of new program offerings. The Source Functional Nutrition group will provide educational sessions, live cooking lessons, bi-weekly drop in Cafe's, 1:1 consultation as well as a library of recipes and videos. The program initiatives Friday, October 27th. Screening to find cancer early is the first pillar (AristotleTM); adjunctive treatment with the CareOncology Protocol is the second; nutritional guidance tailored to the type and stage of the cancer is the third pillar. "25-80% of cancer patients, depending on their age and the type and stage of thecancer, suffer from mal nutrition. This problem has become much more acute since the COVID pandemic as treatment options were delayed and access curtailed. Chemotherapy patients, especially, rely on Oncology Nutrition to help with physical strength and assistance during treatment. Nutritional screening and evaluation, as well as detailed nutritional guidance, are essential to assist with a good outcome" said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. The Source Functional Nutritional offering provides cancer specific nutritional guidance with group information sessions, cooking lessons and one on one sessions. Diet is key to supporting a patient's ability to manage treatment and retain strength. dietary guidance can differ between cancer type and stage of treatment. TheSource program will show participants how to navigate this with concrete tools and recipes. Care Oncology offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Care Oncology has been treating cancer patients since 2013 using patented COC Protocol™?. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use. In addition to the COC Protocol, Care Oncology offers the AVRT program. All of the Care Oncology programs are managed by a multi-disciplinary team that is overseen by an Oncologist and includes Nurse Practitioners and Metabolic Specialists. Care Oncology Clinics also offers AVRT a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Aristotle®? is processed at the Company's clinical laboratory, StageZero Life Sciences Inc., a CAP accredited and CLIA certified high-complex cancer. Reported Earnings • Aug 15
Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.013 loss in 2Q 2022) Second quarter 2023 results: US$0.003 loss per share (improved from US$0.013 loss in 2Q 2022). Revenue: US$793.3k (down 21% from 2Q 2022). Net loss: US$401.5k (loss narrowed 69% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings. Reported Earnings • May 18
First quarter 2023 earnings released: US$0.02 loss per share (vs US$0.006 loss in 1Q 2022) First quarter 2023 results: US$0.02 loss per share (further deteriorated from US$0.006 loss in 1Q 2022). Revenue: US$778.5k (down 41% from 1Q 2022). Net loss: US$1.81m (loss widened 207% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings. Anuncio • May 16
StageZero Life Sciences Ltd. to Report Q1, 2023 Results on May 15, 2023 StageZero Life Sciences Ltd. announced that they will report Q1, 2023 results on May 15, 2023 Reported Earnings • Nov 17
Third quarter 2022 earnings released: EPS: US$0 (vs US$0.033 loss in 3Q 2021) Third quarter 2022 results: EPS: US$0 (improved from US$0.033 loss in 3Q 2021). Revenue: US$799.4k (up 17% from 3Q 2021). Net loss: US$45.1k (loss narrowed 98% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Colorectal Cancer Clinical Advisory Board Larry Cohen was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Aug 17
Second quarter 2022 earnings released: US$0.01 loss per share (vs US$0.067 profit in 2Q 2021) Second quarter 2022 results: US$0.01 loss per share (down from US$0.067 profit in 2Q 2021). Revenue: US$998.2k (up 147% from 2Q 2021). Net loss: US$1.28m (down 130% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Reported Earnings • May 18
First quarter 2022 earnings released: US$0.01 loss per share (vs US$0.12 loss in 1Q 2021) First quarter 2022 results: US$0.01 loss per share (up from US$0.12 loss in 1Q 2021). Revenue: US$1.32m (down 47% from 1Q 2021). Net loss: US$590.5k (loss narrowed 92% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Colorectal Cancer Clinical Advisory Board Larry Cohen was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Apr 02
Full year 2021 earnings released: US$0.11 loss per share (vs US$0.15 loss in FY 2020) Full year 2021 results: US$0.11 loss per share. Revenue: US$5.07m (up 22% from FY 2020). Net loss: US$7.48m (loss widened 9.0% from FY 2020). Reported Earnings • Nov 17
Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.11 loss in 3Q 2020) The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: US$684.3k (down 53% from 3Q 2020). Net loss: US$2.22m (loss narrowed 52% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth. Executive Departure • Sep 01
Interim Chief Financial Officer Carl Solomon has left the company During their tenure, earnings grew by 20% annually compared to the industry average of 20%. On the 28th of August, Carl Solomon left the company after 2.9 in the role. We don't have any record of a personal shareholding under Carl's name. Carl is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 3.92 years. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS US$0.05 (vs US$0.006 loss in 2Q 2020) Second quarter 2021 results: Revenue: US$404.7k (up US$341.3k from 2Q 2020). Net income: US$4.33m (up US$4.60m from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 18
First quarter 2021 earnings released The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$2.48m (up US$2.47m from 1Q 2020). Net loss: US$7.30m (loss widened 170% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 04
Full year 2020 earnings released The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: US$4.15m (up US$4.01m from FY 2019). Net loss: US$6.86m (loss widened 97% from FY 2019). Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 36% per year. Is New 90 Day High Low • Feb 18
New 90-day high: €0.90 The company is up 95% from its price of €0.46 on 19 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period. Is New 90 Day High Low • Jan 14
New 90-day high: €0.60 The company is up 9.0% from its price of €0.56 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period. Is New 90 Day High Low • Dec 17
New 90-day low: €0.39 The company is down 25% from its price of €0.51 on 18 September 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period. Is New 90 Day High Low • Sep 19
New 90-day high: €0.51 The company is up 929% from its price of €0.05 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period.